PBS, Keytruda and NSCLC...., page-3

Something to consider......

Keytruda is now leading the I/O revolution albeit with sub-optimal results.....

If (big if) efti can prove itself as a compatible aid to keytruda to improve

its results meaningfully the value of Immutep will skyrocket......Tacti=mel

has given an early indication of working well with keytruda which no doubt

in my mind influenced Merck to collaborate in US trials.....We still need 

more data to convince the market though......

Also.....

I reckon Immutep are at the newsmakers conference to interest venture

capalists on a cash injection,,,,IMO it's a good idea to do this sort of thing

whilst you have ample funding so as not appear desperate and thus open

to being taken advantage of.....

This company is making all the right moves, both business and research

wise.....